Sarah L. Henkle

A New Mesenchymal Stem Cell (MSC) Paradigm: Polarization into a Pro-Inflammatory MSC1 or an Immunosuppressive MSC2 Phenotype

Ruth S. Waterman, Suzanne L. Tomchuck, Sarah L. Henkle et al. · PLoS ONE · 2010 · 1.2K citations · Full text

Life Sciences, Cell Biology, Immunology +17

The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells

Seth B. Coffelt, Frank C. Marini, Keri L. Watson et al. · Proceedings of the National Academy of Sciences · 2009 · 286 citations

Medicine, Cancer Biology, Oncology +15

Mesenchymal Stem Cell 1 (MSC1)-Based Therapy Attenuates Tumor Growth Whereas MSC2-Treatment Promotes Tumor Growth and Metastasis

Ruth S. Waterman, Sarah L. Henkle, Aline M. Betancourt · PLoS ONE · 2012 · 196 citations · Full text

Medicine, Cell Biology, Oncology +15

Toll-Like Receptor 3 and Suppressor of Cytokine Signaling Proteins Regulate CXCR4 and CXCR7 Expression in Bone Marrow-Derived Human Multipotent Stromal Cells

Suzanne L. Tomchuck, Sarah L. Henkle, Seth B. Coffelt et al. · PLoS ONE · 2012 · 18 citations · Full text

Life Sciences, Cell Biology, Immunology +17